- Inauguration of Angelika Amon research building in Vienna
- Sustainable research building at a cost of EUR 60 million offers modern office and laboratory space
- Over the past five years, Boehringer’s capital investments reached EUR 6.0 billion
Boehringer Ingelheim is one of the world’s leading research-oriented pharmaceutical companies. The clinical pipeline is constantly being further developed, and Boehringer Ingelheim expects new approvals also in oncology in the coming years.
A significant investment in the future is the new Angelika Amon Research Building, which opened on September 25, in the presence of guests from the political and scientific communities. The modern and sustainable building provides ideal conditions for researchers on 11 floors, where 150 people work on promising therapeutic approaches against cancer in an environment equipped with state-of-the-art research equipment. It is named after the internationally renowned Viennese cancer researcher Angelika Amon (1967–2020) who had a close relationship with Boehringer Ingelheim. The investment sum of approximately EUR 60 million is another testament to Boehringer Ingelheim’s dedication to cancer research.
However, the completion of the new research building is only one of many investments. To support the company’s growth, Boehringer announced last year a 5-year plan, involving EUR 7.0 billion in capital investment. In 2023, capital expenditure reached EUR 1.2 billion under this program. Over the past five years, Boehringer’s capital investments have totaled EUR 6.0 billion.
Hope in the fight against cancer
R&D investments in Human Pharma reached EUR 5.8 billion in 2023, representing about 25% of Human Pharma net sales, ranking Boehringer Ingelheim among the top R&D investors in the industry. “Our goal is to create more health for humans and animals,” says Paola Casarosa, Head of Innovation Unit, explaining the focus on a promising and broad portfolio in the fight against cancer. “Especially in the field of oncology, there is still a massive unmet medical need. We are working with great enthusiasm to make cancer a treatable disease.”
Norbert Kraut, Global Head of Cancer Research, says “Our declared goal is to cure cancer. The big challenge is that cancer is not a single disease, but a term for different diseases of different organs. In the future, around one third of the new products at Boehringer Ingelheim will come from oncology.”
New high-tech facility
The latest technologies and laboratories allow scientists to more quickly achieve their goal of developing innovative therapies for people living with cancer. The new building, with a gross floor space of approximately 11,000 sqm, is also state-of-the-art in terms of sustainability. Photovoltaic arrays on the roof and the facade of the 38 m high building save 45 tons of CO2 per year. Electrochromic glass automatically darkens with sunlight and reduces cooling requirements by 30%.
Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at .
Intended Audiences Notice
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
References
Attachments